Further experimental and observational studies of high quality, with adequate number of events and follow-up time, need to examine the potential role of SGLT2-is in subclinical atherosclerosis and ASCVD events, not only in those with diabetes and pre-diabetes but also in normoglycemic individuals. This evidence concerns the gene SLC5A2 and diabetes mellitus.